How to Get Trulicity (Dulaglutide) in Oklahoma

Who Can Prescribe Trulicity in Oklahoma

Any Oklahoma-licensed prescriber with active prescriptive authority can write a Trulicity prescription. That includes physicians (MD and DO), nurse practitioners, and physician assistants. Oklahoma grants NPs full practice authority after a supervised transition period of 2 to 000 hours, per Oklahoma Senate Bill 1373, so NPs who have completed that requirement can prescribe GLP-1 receptor agonists independently.

Primary care providers handle the majority of GLP-1 prescriptions nationally. A 2021 analysis published in Diabetes Care found that 68% of GLP-1 receptor agonist prescriptions originated from primary care rather than endocrinology offices 1. Oklahoma mirrors this pattern. The state has only 98 practicing endocrinologists for a population of roughly 4 million, according to the Endocrine Society's workforce data, which means most patients in rural counties will get their Trulicity prescription from a family medicine or internal medicine provider.

If your current provider is unfamiliar with GLP-1 receptor agonists, telehealth platforms staffed by obesity medicine and endocrinology specialists offer a practical alternative. These platforms operate legally in Oklahoma and can prescribe brand-name Trulicity directly.

Telehealth Prescribing: How It Works in Oklahoma

Oklahoma law permits synchronous telehealth visits for prescribing schedule and non-schedule medications, including Trulicity. No prior in-person visit is required for a telehealth provider to write a new prescription. The Oklahoma Medical Board confirmed this framework under the Ryan Haight Act federal guidelines and state-level telehealth parity rules that were made permanent after the COVID-era expansions.

A typical telehealth pathway for Trulicity looks like this. You complete a medical intake that includes your diabetes history, current A1c, body weight, comorbidities, and medication list. A licensed provider reviews these records, conducts a live video visit (usually 15 to 25 minutes), and determines whether dulaglutide is clinically appropriate. If so, they transmit the electronic prescription to the pharmacy you select.

Telehealth visits can often be scheduled within 48 to 72 hours. Some platforms offer same-day appointments. The prescription itself transmits electronically to Oklahoma pharmacies within minutes of the visit. First fills may take an additional 3 to 7 business days if prior authorization is required by your insurer.

Labs Required Before Starting Trulicity

Most prescribers in Oklahoma will order baseline labs before initiating dulaglutide. The American Diabetes Association (ADA) Standards of Care 2024 recommend the following for patients starting injectable GLP-1 therapy:

Required labs:

• Hemoglobin A1c (confirms glycemic status and treatment threshold)
• Fasting blood glucose
• Basic metabolic panel (BMP), which includes serum creatinine and eGFR
• Lipid panel

Commonly ordered but not always mandatory:

• Thyroid function tests (TSH, free T4), given the FDA boxed warning about medullary thyroid carcinoma risk in rodents
• Hepatic function panel (ALT, AST)
• Amylase and lipase (baseline pancreatic enzymes)

Dulaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. The FDA-approved prescribing information states that Trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. Your prescriber should ask about thyroid cancer history before writing the prescription.

Labs drawn within the prior 90 days are generally accepted. If you have recent bloodwork from another provider, you can upload those results during your telehealth intake to avoid duplicate testing. Quest Diagnostics operates 47 patient service centers across Oklahoma, and LabCorp has 22 locations, so in-person draws are accessible in most metro and suburban areas.

Oklahoma Medicaid (SoonerCare) Coverage

SoonerCare does not cover Trulicity for type 2 diabetes. This is a significant access barrier for the approximately 900,000 Oklahomans enrolled in Medicaid following the state's 2021 expansion. The Oklahoma Health Care Authority (OHCA) preferred drug list favors older, less expensive diabetes medications as first-line injectable therapy.

Patients on SoonerCare who need a GLP-1 receptor agonist may have access to other agents on the preferred list, but dulaglutide specifically is excluded. Providers can submit exceptions, though approval rates for non-preferred GLP-1s on SoonerCare are low.

For patients who lose Medicaid coverage during redetermination cycles, transitioning to a commercial plan or marketplace plan during open enrollment may restore access to Trulicity. The ADA's 2024 Standards of Care explicitly state that "cost-related nonadherence to GLP-1 receptor agonist therapy is associated with increased hospitalizations and A1c deterioration" 3.

Commercial Insurance and Prior Authorization

Most commercial insurers in Oklahoma cover Trulicity but require prior authorization (PA). Blue Cross Blue Shield of Oklahoma, UnitedHealthcare, and Aetna all list dulaglutide on their formularies, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Copays at Tier 3 range from $50 to $150 per month; Tier 4 copays can reach $200 to $300.

What prior authorization requires:

Your prescriber's office submits documentation showing:

1. A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
2. Current A1c value (most plans require A1c of 7.0% or higher)
3. Failure of, intolerance to, or contraindication to metformin
4. Duration of metformin trial (typically 90 days minimum)
5. Clinical rationale for selecting dulaglutide over preferred alternatives

PA decisions usually arrive within 48 to 72 hours for commercial plans. Expedited reviews (24 hours) are available when the prescriber certifies medical urgency. If denied, your provider can submit a peer-to-peer appeal.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death by 12% compared to placebo (HR 0.88 to 95% CI 0.79-0.99) over a median 5.4-year follow-up 4. This cardiovascular benefit data strengthens PA appeals for patients with established cardiovascular disease or multiple risk factors.

Manufacturer Savings and Patient Assistance

Eli Lilly offers two programs that directly reduce out-of-pocket costs for Oklahoma patients:

Trulicity Savings Card: Commercially insured patients may pay as little as $25 per month for up to 24 months. The card covers up to $150 per fill. It is not valid for patients using government insurance (Medicare, Medicaid, Tricare, VA).

Lilly Cares Foundation: Uninsured patients or those who do not qualify for the savings card can apply for free medication through the Lilly Cares patient assistance program. Eligibility is income-based, typically set at 400% of the federal poverty level or below. Approval provides a 12-month supply, renewable annually.

A 2023 analysis in JAMA Internal Medicine found that manufacturer copay assistance programs reduced GLP-1 receptor agonist abandonment rates by 41% at the pharmacy counter 5. For Oklahoma patients facing the state's relatively high uninsured rate of 14%, these programs can be the difference between starting therapy and not.

Pharmacy Options in Oklahoma

Oklahoma patients have three main channels for filling a Trulicity prescription.

Retail chain pharmacies. CVS, Walgreens, and Walmart pharmacies across Oklahoma stock Trulicity. Availability is generally reliable in metro areas (Oklahoma City, Tulsa, Norman, Broken Arrow) but may require 1 to 2 day ordering in rural locations. Trulicity is a cold-chain medication requiring refrigeration at 36°F to 46°F (2°C to 8°C), so pharmacies must maintain proper storage.

Specialty pharmacies. Some insurers mandate that Trulicity be filled through a designated specialty pharmacy, particularly for patients on high-deductible plans. Accredo, Express Scripts Specialty, and OptumRx Specialty all ship to Oklahoma addresses with temperature-controlled packaging.

503A compounding pharmacies. Oklahoma licenses 503A compounding pharmacies that may prepare dulaglutide formulations for individual patient prescriptions. These pharmacies operate under the Oklahoma State Board of Pharmacy and must comply with USP 797 and 800 standards. Compounded GLP-1 products may cost less than brand-name Trulicity, but they are not FDA-approved finished products. The FDA's guidance on compounding clarifies the regulatory boundaries for 503A preparations.

Transferring a Trulicity Prescription to Oklahoma

If you are relocating to Oklahoma from another state, your existing Trulicity prescription can transfer to an Oklahoma pharmacy. Prescription transfers for non-controlled substances like dulaglutide are straightforward.

Contact your new Oklahoma pharmacy and provide your current pharmacy's name, phone number, and prescription number. The receiving pharmacist will initiate the transfer directly. Oklahoma Board of Pharmacy rules allow one transfer per prescription for non-controlled medications.

If your prescription has no remaining refills, you will need a new prescription from an Oklahoma-licensed provider. Telehealth platforms can issue this quickly if you have recent labs and medical records documenting your diabetes management history. Most telehealth services accept out-of-state medical records to establish continuity of care.

Dosing and Titration Schedule

Trulicity is available in five dose strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg, all in single-use pre-filled pens administered once weekly 2.

The standard titration protocol starts at 0.75 mg weekly for at least 4 weeks, then increases to 1.5 mg weekly. If additional glycemic control is needed after at least 4 weeks at 1.5 mg, the dose can increase to 3.0 mg, and then to 4.5 mg. Each step requires a minimum 4-week interval.

The AWARD-11 trial (N=1,842) showed that the 3.0 mg and 4.5 mg doses produced additional A1c reductions of 0.24% and 0.40% respectively beyond the 1.5 mg dose 6. These higher doses became available after the 2020 FDA approval of the 3.0 mg and 4.5 mg pens.

Gastrointestinal side effects (nausea, diarrhea, vomiting) are dose-dependent and most common during titration. In AWARD-11, nausea occurred in 16% of patients on 4.5 mg versus 12% on 1.5 mg. Gradual titration minimizes these effects. Most GI symptoms resolve within 4 to 8 weeks at a stable dose.

Timeline: From First Visit to First Injection

Expect the following timeline for a typical Oklahoma patient starting Trulicity:

• Day 1: Complete telehealth or in-person intake; labs ordered
• Days 2-5: Labs drawn and resulted
• Day 5-7: Provider visit (video or in-person), prescription written, PA submitted
• Days 7-10: PA decision returned (48-72 hours for commercial insurance)
• Days 10-14: Prescription filled, medication shipped or picked up
• Day 14: First injection

Total time from initial contact to first dose: approximately 10 to 14 days. Patients with recent labs and no PA requirement can compress this to 3 to 5 days. Cash-pay patients who skip PA entirely can sometimes receive medication within 48 hours of their prescription being written.

The REWIND trial enrolled patients who had been on dulaglutide for a median of 5.4 years, confirming long-term tolerability 4. Dr. Hertzel Gerstein, the trial's principal investigator, stated: "Dulaglutide's cardiovascular benefit was consistent regardless of whether participants had established cardiovascular disease at baseline."

Oklahoma-Specific Considerations

Oklahoma ranks 45th nationally in diabetes prevalence, with 12.7% of adults diagnosed, according to the CDC's National Diabetes Statistics Report [7]. Access to endocrinologists is limited outside the Oklahoma City and Tulsa metro corridors, making telehealth a practical necessity for many patients in western and southeastern Oklahoma.

The Oklahoma Insurance Department requires commercial plans sold on the state exchange to cover at least one GLP-1 receptor agonist per formulary tier. This does not guarantee Trulicity specifically, but it ensures that a prescriber can appeal for dulaglutide if the preferred GLP-1 is clinically inappropriate or poorly tolerated.

Oklahoma's 2024 legislative session did not pass any bills restricting telehealth prescribing of diabetes medications. The regulatory environment remains stable for patients seeking Trulicity through virtual care.

Patients with type 2 diabetes and an A1c above 9.0% should start pharmacotherapy immediately without waiting for lifestyle interventions alone, per the ADA Standards of Care [3]. Dulaglutide 0.75 mg weekly is the recommended starting dose regardless of whether the patient has tried oral agents first.